[1]安邦胜,李婷.解炎汤加味治疗成人社区获得性肺炎痰热壅肺证疗效观察[J].西部中医药,2025,38(07):138-140.[doi:10.12174/j.issn.2096-9600.2025.07.27]
　AN Bangsheng,LI Ting.Clinical Observation on Modified Inflammation-relieving Decoction in the Treatment of Community Acquired Pneumonia of Phlegm-heat Obstructing in the Lung Pattern[J].Western Journal of Traditional Chinese Medicine,2025,38(07):138-140.[doi:10.12174/j.issn.2096-9600.2025.07.27]
点击复制

解炎汤加味治疗成人社区获得性肺炎痰热壅肺证疗效观察()

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
38
期数:
2025年07期
页码:
138-140
栏目:
临床研究
出版日期:
2025-07-15

文章信息/Info

Title:
Clinical Observation on Modified Inflammation-relieving Decoction in the Treatment of Community Acquired Pneumonia of Phlegm-heat Obstructing in the Lung Pattern
作者:
安邦胜, 李婷
长春中医药大学附属医院定西医院，甘肃 定西 743000
Author(s):
AN Bangsheng, LI Ting
Dingxi Hospital of TCM, Dingxi 743000, China
关键词:
社区获得性肺炎; 解炎汤; 肺功能; 炎症
Keywords:
community acquired pneumonia; inflammation-relieving decoction; lung function; inflammation
分类号:
R256.15
DOI:
10.12174/j.issn.2096-9600.2025.07.27
文献标志码:
B
摘要:
目的观察解炎汤加味治疗成人社区获得性肺炎（community acquired pneumonia，CAP）痰热壅肺证的临床疗效。 方法选取CAP痰热壅肺证患者共计66例，根据随机数字表法分成2组，每组33例。对照组给予静脉注射头孢噻肟舒巴坦钠及口服羧甲斯坦口服液治疗；观察组在对照组治疗的基础上加服解炎汤加味。两组疗程均为10天。比较两组临床肺部感染评分（clinical pulmonary infection score，CPIS）、肺功能、炎性指标、临床疗效。 结果治疗后，两组CPIS评分明显减少，且观察组减少更明显（P＜0.05）；治疗后两组肺活量（vital capacity，VC）、最大自主分钟通气量（maximum voluntary minute ventilation volume，MVV）及第一秒用力呼气量（forced expiratory volume in one second，FEV1）明显增加，观察组增加更明显（P＜0.05）；治疗后两组白细胞计数和中性粒细胞百分比减少，观察组减少更明显（P＜0.05）；观察组临床总有效率［96.97%（32/33）］高于对照组［75.76%（25/33）］（P＜0.05）。 结论解炎汤加味治疗成人CAP痰热壅肺证能减轻肺部炎症及临床症状，改善肺功能，提高疗效。
Abstract:
ObjectiveTo observe clinical effects of modified inflammation-relieving decoction in treating community acquired pneumonia (CAP) of phlegm-heat obstructing in the lung pattern. MethodsAll 66 CAP patients of phlegm-heat obstructing in the lung pattern were selected, and divided into two groups according to random number table method with 33 cases in each group. The control group adopted cefotaxime sulbactam sodium for intravenous injection and carbocysteine oral solution for oral administration, and the observation group orally took modified inflammation-relieving decoction based on the therapy that the control group accepted. To compare clinical pulmonary infection score (CPIS), lung function, inflammatory indexes and clinical effects between the two groups. ResultsAfter the treatment, CPIS scores were significantly reduced in the two groups, and the decrease of the observation group was more evident (P<0.05); after the treatment, the increase in VC, MVV and FEV1 was more noticeable in the two groups, and the increase of the observation group was more obvious (P<0.05); after the treatment, the reduction in leucocyte count and the percentage of neutrophile granu-locyte was found in the two groups, and the reduction of the observation group was more noticeable (P<0.05); clinical total effective rate of the observation group was [96.97%(32/33)], higher than [75.76%(25/33)] of the control group (P<0.05). ConclusionModified inflammation-relieving decoction in treating phlegm-heat obstruc-ting in the lung type of CAP could alleviate the inflammation in the lung and clinical symptoms, improve lung function and enhance clinical effects.

相似文献/References:

[1]张兰豫.白银地区5岁以下儿童社区获得性肺炎不同年龄、季节及细菌分布特征分析[J].西部中医药,2016,29(02):92.
　ZHANG Lanyu.Analysis of the Ages, Seasons and Bacterial Distribution Features of the Children under Five Years with Community-acquired Pneumonia[J].Western Journal of Traditional Chinese Medicine,2016,29(07):92.

备注/Memo

备注/Memo:
安邦胜（1973—），男，副主任医师。研究方向：呼吸系统感染性疾病的诊断与治疗。Email：anbsheng@126.com。国家自然科学基金面上项目（81774273）。
更新日期/Last Update: 2025-07-15